Advancements in surgery have made it possible to resect cancers that had previously been regarded as incurable. Similarly, new developments in radiation oncology have helped improve the outlook for patients with locally advanced or recurrent head and neck cancers. Among these advancements are refinements in altered fractionation, three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, stereotactic radiosurgery andfractionatedstereotactic radiotherapy, neutron-beam radiotherapy, charged-particle radiotherapy, and intraoperative radiotherapy. These recent developments have allowed radiation oncologists to escalate the dose of radiation delivered to tumors while minimizing the dose delivered to surrounding normal tissue. Additionally, more continues to be learned about the optimum delivery ofchemotherapy. This article provides an update on the status of these new developments in the treatment of head and neck cancers.
Introduction
Cancers of the head and neck region constitute 3% of all cancers; approximately 40,000 new cases occur each year in the United States. 1 Smoking is the most common cause of head and neck cancers.' Alcohol abuse and poor oral hygiene are other common risk factors.' The role of genetic abnormalities is just now beginning to be elucidated. For example, p53 gene mutations are frequently observed in patients with head and neck cancers.3,4Infection with Epstein-Barr virus or human papillomavirus types 6, 11, 16, or 18 might also playa role in the development of head and neck malignancies."
Patients with head and neck cancer should be placed under the care of a multidisciplinary team whose members can provide not only prospective treatment recommendations, but deliver dental care along with nutritional, psychological, and social support. The aims of a multidisciplinary approach are to maximize the duration of disease-free and overall survival while minimizing morbidity.
Several recent advances have been made in radiation techniques and planning for these patients, and more continues to be learned about chemotherapy. In this article, we discuss this important progress.
Conventional radiotherapy
Radiotherapy has been used to treat cancer for more than a century. The dose of radiation is typically expressed in terms of gray (Gy) units (l Gy = 100 cGy = 100 rads), which denote the amount of energy deposited in tissue per unit of mass (J/kg).
The most common method ofdelivering external-beam radiotherapy (EBRT) is by linear accelerators, which produce photons (x-rays). These machines use a penetrating, high-energy (4 to 6 MV) x-ray beam to minimize the dose of radiation that is delivered to the skin. In contrast, electrons and superficial x-rays are more limited in their depth of tissue penetration, and they are suitable only for treating superficial lesions. Radiation therapy can also be delivered via brachytherapy, which involves the implantation of radioisotopes such as iridium 192 (Ir l 92 ) or cesium 137 (Cs 137 ) directly into unresectable cancers. During brachytherapy, gamma rays are emitted by the radioactive source, and they have the same biologic effect as x-rays, For a given degree oftumor-cell killing, the delivery of multiple small doses of radiation (fractionation) carries a lower risk of late complications than does the delivery of a single large dose. For this reason, fractionation has been a cornerstone of radiotherapy since the 1920s. In general, 44 to 50 Gy of radiation, delivered in increments of 1.8 to ENT-Ear, Nose & Throat Journal • October 2001 CHOU, WILDER, WONG, FORSTER 2.0 Gy per fraction, are administered to regions that have a risk of 15% or more of harboring microscopic disease." Between 66 and 70 Gy are usually prescribed for primary tumors measuring 2 em or less. 7 When radiotherapy alone is delivered to a patient with more advanced disease, doses of 70 Gy or more are necessary to control the primary tumor and involved nodes. ' As a rule of thumb, the dose of radiation required for locoregional control increases as tumor size increases. In patients with lymphadenopathy, EBRT alone can control more than 90% of neck nodes that measure 2 em or less." EBRT at doses ono Gy or more sterilizes only approximately 80% of nodes that measure 2 to 3 em." Lymph nodes that are larger than 3 em are rarely controlled with EBRT alone; they usually require a planned neck dissection. An exception to this general rule applies to lymph node metastases of nasopharyngeal and tonsillar carcinomas; these metastases are more radiosensitive than are metastases that spread from primary tumors at other sites.
Altered fractionation
There has recently been an increase in interest in altered fractionation schedules that differ from the traditional once-daily approach. Locoregional control in advanced head and neck cancers is suboptimal when radiotherapy alone is administered on a once-daily schedule. For radiobiologic reasons, altered fractionation schedules-in which two or three doses of radiation are delivered daily (at least 6 hours apart to minimize toxicity)-have been actively explored in the treatment of advanced head and neck cancers.
Hyperfractionation. Hyperfractionation typically refers to twice-daily delivery. Overall, hyperfractionation delivers a higher total dose than once-daily fractionation in approximately the same amount of treatment time; radiation is delivered in more, but smaller, doses. By using a smaller dose per fraction than once-daily fractionation, hyperfractionation allows for the delivery of a higher total dose while remaining within the tolerance of late-responding tissues. As a result, hyperfractionation can decrease the risk of late complications while achieving the same or better tumor control as once-daily delivery.
Accelerated fractionation. Accelerated fractionation is a means of decreasing the overall duration of treatment in an effort to reduce the repopulation of tumor cells in rapidly proliferating cancers. Repopulation (tumor-cell regeneration) tends to increase over time when the overall duration of treatment is protracted. By reducing the overall duration of treatment and thereby retarding repopulation, the likelihood of tumor control can be increased.
Concomitant-boost technique. A variant of accelerated fractionation is the concomitant-boost technique. 706 With this technique, treatment is delivered once daily for the first 3.5 weeks and then twice daily during the final 2 to 2.5 weeks, when tumor cells can begin to repopulate more rapidly.
Accelerated hyperfractionation. Accelerated hyperfractionation has also been studied as a way of increasing tumor-cell killing without increasing the risk of late complications. This hybrid regimen incorporates features of both accelerated fractionation and hyperfractionation.
Numerous trials have suggested that the different types of altered fractionation have advantages over conventional once-daily dosing."!" For example, the European Organization for Research and Treatment of Cancer conducted a prospective, randomized trial to compare twicedaily radiotherapy with 80.5 Gy in 70 fractions versus once-daily radiotherapy with 70 Gy in 35 to 40 fractions in patients with stage II or III oropharyngeal carcinoma (excluding carcinomas of the base of the tongue)." The researchers found that locoregional control at 5 years was better with the twice-daily treatment (59 vs 40%; p = 0.007). There was also a trend toward better overall survival at 5 years with altered fractionation (40 vs 30%; p = 0.08). There was no difference in late toxicity between the two arms.
Similar locoregional control and overall survival rates have been observed in patients with slightly more advanced disease (stage III or IV) whose treatment included the concomitant-boost technique.v" The Radiation Therapy Oncology Group recently reported the findings of its prospective, randomized, 2-year comparison of once-daily fractionation, hyperfractionation, and two variants of accelerated fractionation." This study included 1,113 patients who had stage III or IV cancer of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx or stage II cancer of the base of the tongue and hypopharynx. The investigators reported that patients who were treated with either hyperfractionation or a concomitantboost technique experienced significantly better locoregional control (p = 0.045 and p = 0.050, respectively) than did those who were treated with once-daily fractionation. The differences in overall disease-free survival rates were not statistically significant, but there was a trend in favor of the two altered fractionation treatments (p =0.067 and p =0.054, respectively.)
Radiotherapy techniques
Three-dimensional conformalradiotherapy. When earlystage disease is treated with radiotherapy, radiation oncologists have traditionally used two or three fields. For patients with more advanced disease, they have typically used a three-field technique that includes coverage of the primary site and the regional lymph nodes. The three fields typically include two opposed lateral fields that are matched with a low anterior neck field (figure 1).
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RECENT ADVANCES IN RADIOTHERAPY FOR HEAD AND NECK CANCERS A B Figure 1A &B. In this patientwith tonsillarfossa carcinoma, the conventional three-field technique-including opposed lateral fields and a matched low anteriorneckfield-is used. Clips mark the craniocaudal extent ofthe tumor. Note the "shrinking field " technique, in which thefield size decreases toward the end ofthe radiotherapy. As a result, a high dose of radiation is delivered only to the area at greatest risk for recurrence. (AP = anterior field; RT =right lateral field; 100 SSD =100 em distance from x-ray source to the skin.) Volume 
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Recent technical advances have led to the development of techniques that differ from these traditional two-and three-field approaches, and these newer techniques have been used increasingly in an attempt to raise the likelihood of cure. One of these techniques is three-dimensional conformal radiotherapy (3D-CRT). With 3D-CRT, sophisticated computer programming is used to determine the optimal beam shape and field arrangement. In addition, a new device, the multileaf collimator, allows for the collimation of the x-ray beam during treatment. The tumor and the regions at risk for.microscopic extension are contoured on each axial computed tomography (CT) slice. The tumor volume is then visualized in three dimensions. A physicist and dosimetrist work together to construct a beam arrangement that will deliver the desired therapeutic dose to the tumor volume while minimizing the amount of radiation that will be delivered to the adjacent normal tissues.
The use of 3D-CRT has been investigated as a treatment for several head and neck cancers, including skull base tumors. For example, Leibel et al compared 3D-CRT plans with conventional two-dimensional radiotherapy plans in 15 patients with nasopharyngeal carcinoma." They found that the 3D-CRT plans were superior to the two-dimensional plans in terms ofboth tumor control and reduction of normal-tissue complications. The probability of tumor control was 15% higher with 3D-CRT. Emami et al also demonstrated that 3D-CRT treatment plans were superior to conventional radiotherapy plans for patients with head and neck cancer. 16 Moreover, Perez et al reported that acute toxicity with 3D-CRT for head and neck cancer was comparable to or less than that observed with conventional radiotherapy. 17 Multileaf collimators significantly shorten the daily treatment time required to administer 3D-CRT. 18 Gademann et al reported promising results with 3D-CRT in 195 patients who had tumors of the head, neck, or brain.'? After a median followup of 22 months, 95% of patients treated with 3D-CRT throughout their entire course of radiotherapy were still alive, versus 86% of those who received 3D-CRT only during their final weeks of radiotherapy. As was the case in other studies.v-" Gademann et al found that morbidity with 3D-CRT compared favorably with that of conventional radiotherapy.
Latz et al described the outcomes of 13 patients whose clival chordomas were treated with 3D-CRT to a median dose of 70 Gy.21 After a median followup of 32 months, 120fthe 13 patients (92.3%) were still alive. The local control rate was 69%. Only one patient developed endocrine dysfunction that required hormone replacement. No complication involving the optic pathway, cranial nerves, or brainstem was observed.
Intensity-modulated radiation therapy. Under computer guidance, "dynamic" multileafcollimators can change reported with near1y all antibacterial agents, including amoxicillin/clavulanate potassium, and has ranged in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment With antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of ..antibioticassociated colitis:' After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically. effective against Clostridium difficile colitis. Use Augmentin ES-600 cautiously In patients With evidence of hepatic dysfunction. Hepatic toxicrtv associated With the use of arnoxicrllin/clavulanate potassium is usually reversible. On rare occaSions, deaths have been reported (less than 1 death reported per estimated 4 million prescnptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. (See CONTRAINDICATIONS and ADVERSE REACTIONS-LIVer.) PRECAUTIONS: General: While amoxicillin/clavulanate possesses the characteristiC low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic and hematopoietic function, is advisable if therapy is for longer than the drug is approved for administration. A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash. Thus, ampicillin class antibiotics should not be administered to patients with mononucleosis. The possibility. of superinfections with mycotic or bacterial pathogens should be kept In mind durinq therapy. If superintections occur (usually involving Pseudomonas or Candida), the drug should be discontinued and/or appropriate therapy instituted. Information for the Patients: Augmentin ES-600 should be taken every 12 hours with a meal or snack to reduce the possibility of gastrointestinal upset. If diarrhea develops and is severe or lasts more than 2 or 3 days, call your doctor. Be sure your child completes the entire prescribed course of treatment, even if he/she begins to feel better after a few days. Keep suspension refrigerated. Shake well before using. When dosing a child with Augmentin ES-600 suspension (liqurd), use a dosing spoon or medicine dropper. Be sure to. rinse the spoon or dropper after each use. Bottles of Augmentin ES-600 suspension may contain more liquid than required. Follow your doctor's instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine. Phenylketonurics: Each 5 mL of the 600 mg/5 mL Augmentin ES-600 suspension contains 7 mg phenylalanine. Drug Interactions: Probenecid decreases the renal tubular secretion of amoxlcillin. Concurrent use with Augmentin ES-600 may result in increased and prolonged blood levels of amoxicillin. Co-administration of probenecid cannot be recommended. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with Augmentin ES-600 and allopurinol administered concurrently. In common with other broad-spectrum antibiotics, amoxicillin/clavulanate may reduce the efficacy of oral contraceptives. Drug/Laboratory Test Interaction.s:. Oral adrninlstration of Augmentin will result in high urine concentrations of amoxicillin. High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose In urine using Clinitest$, Benedict's Solution or Fehling's Solution. Since this effect may also occur with amoxicillin and therefore Augmentin ES-600, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Cllnistix'" or Tes-Tape'")be used. Following administration of ampicillin to pregnant women a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with amoxicillin and therefore Augmentin ES-600. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to evaluate carcinogenic potential. The mutagenic potential of Augmentin was investigated in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse lymphoma forward mutation assay, and in VIVO with mouse micronucleus tests and a dominant lethal test. All were negative apart from the in vitro mouse lymphoma assay where weak activity was found at very high, cytotoxic concentrations. Augmentin at oral doses of up to 1200 mg/kg/day (5.7 times the maximum adult human dose based on body surface area) was found to have no effect on fertility and reproductive performance in rats, dosed With a 2:1 ratio formulation of amoxicillin:c1avulanate. Teratogenic effects. Pregnancy (Category B): Heproducnon studies performed In pregnant rats and mice given Augmentm at oral dosages up to 1200 mg/kg/day (4.9 and 2.8 times the maximum adult human oral dose based on body surface area, respectively), revealed no evidence of harm to. the fetus due to Augmentin. There are, however, no adequate and well-controlled studies In pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Labor and Delivery: Oral ampicillin class antibiotics are generally poorly absorbed during labor. Studies In gUln~a pigs have shown that intravenous administration of ampicillin decreased the uterine tone. frequency of contractions, height of contractions and duration of contractions. However, it is not known whether the use of Augmenttn in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor. or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn Will be necessary. Nursing Mothers: Ampicillin class antibiotics are excreted in human milk; therefore, caution should be exercised when Augmentin is administered to a nursing woman, Pediatric Use: Safety and efficacy of Augmenttn ES-600 in infants younger than 3 months of age have not been established. Safety and efficacy of Augmentin ES-600 have been demonstrated for treatment of acute otitis media in infants and children 3 months of age to 12 years of age (see Description of Clinical Studies In complete prescribing information). ADVERSE REACTIONS: Augmentin ES-600 is generally well tolerated. The majority of side effects observed in pediatric clinical trials of acute otitis media were either mild or moderate, and transient in nature; 4.4% of patients discontinued therapy because of drug-related side effects. The most commonly reported Side effects with probable or suspected relationship to Augmenttn ES-600 were contact dermatitis, i.e.. diaper rash (3.5%), diarrhea (2.9%), vomiting (2.2%). moniliasis (1.4%). and rash (1.1 %). The most common adverse experiences leading to withdrawal that were of probable or suspected relationship to Augmentin ES-600 were diarrhea (2.5%1 and vomiting (1.4%). The followino adverse reactions have been reported for ampicillin class antibiotics: Gastrointestinal: Diarrhea, nausea, vomiting, Indigestion, gastritis, stomatitis, glossitis, black "hairv" tongue, mucocutaneous candidiasis. enterocolitis, and hemorrhagic/ pseudomembranous colitis. Onset of pseudomembranous colitis~y~ptoms may occur during or after antibiotrc treatment. (SeeWARNINGS.) Hvpersensiuvit» Reactions: Skin rashes, pruritus, urticana, angioedema, serum Sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia and frequently fever). erythema multiforme (rarely Stevens-Johnson Syndrome), acute generalised exanthematous pustulosis and an occasional case of exfoliative dermatitis (includin~tOXIC epidermal necrolysis) have been reported. These reactions may be controlled With antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, the dru9 should be discontinued, unless the opinion of the phvslcian dictates otherwise, Serious and occasional fatal hypersensitivity (anaphylactic) reactions can occur With oral perucillin. (See WARN.INGS.) Liver: A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated With ampicillin class antrbiottcs but the Significance of these findings is unknown. Hepatic dysfunction, including increases In serum transarmnases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase, has been infrequently reported with Augmentin. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histoloqic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of Signs/symptoms of hepatic dysfunction may occur dunnc or several weeks after therapy has been discontmued.The hepatic dysfunction, which may be severe, IS usually reversible. On rare occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwrde}, These have generally been cases associated with senous underlying diseases or concomitant medications. Renal: Interstitial nephritis and hematuria have been reported rarely. Hemic and LymphatIC Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrornbocvtopenic purpura, eosinophuia, leukopenia and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted In less than 1% of the patients treated with Augmentin. There have been reports of increased prothrombin time in patients receiving Augmentin and anticoagulant therapy concomitantly. Central Nervous System: Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, 1n5.0mnla, and reversible hyperactivity have been reported rarely. Miscellaneous: Tooth discoloration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discoloration as it can usually be removed by brushing. their shape during treatment, thereby giving rise to intensity-modulated radiation therapy (IMRT). IMRT can deliver radiation more conformally than 3D-CRT can, which allows for the delivery of higher doses. IMRT differs from 3D-CRT in that each x-ray beam is broken up into many "beamlets," and the intensity of each beamlet can be adjusted individually. As a result, IMRT has a significant advantage over 3D-CRT in inverse planning, which is the process by which a physicist, using a computer program, starts with the dose distribution desired by the radiation oncologist and works backward to determine the intensity of every beamlet necessary to achieve that distribution. By contrast, treatment planning with 3D-CRT is an exercise in trial and error.
With the aid of the multileaf collimator, IMRT fields can treat targets more efficiently because they allow the physician to better conform the high-dose region to the tumor. As a result, a higher dose of radiation can be safely delivered to the tumor. Several studies have demonstrated the feasibility and potential advantages of IMRT in the treatment of head and neck cancers. 15, [22] [23] [24] The results of preliminary clinical studies by various investigators have been promising.v'"
IMRT is especially useful in treating tumors of the nasal cavity, ethmoid sinus, sphenoid sinus, and base of the skull, areas where the risks of optic neuropathy and retinopathy following conventional radiotherapy are relativelyhigh (figures 2, 3, and 4). In a study of nasal cavity, ethmoid sinus, and sphenoid sinus cancers, Parsons et al reported that 33% of patients treated with radiotherapy alone developed unilateral blindness between 17 and 90 months after treatment. 28 Stereotactic radiosurgery andfractionated stereotactic radiotherapy. Stereotactic radiosurgery provides the precise delivery of a single large dose of radiation to a targetthattypically measures less than 3.5 ern in diameter. The procedure can be administered by a linear accelerator, gamma knife, or cyclotron. By limiting treatment to a small target, the physician can ensure a steep fall-off in the amount of radiation that is administered to adjacent normal tissue. A stereotactic frame is used to immobilize the patient's head during treatment. This frame also serves as a reference marker, allowing for precise target localization in a three-dimensional space. Stereotactic radiosurgery has been used to treat skull base tumors and nasopharyngeal carcinomas. 29, 30 Like fractionated EBRT, fractionated stereotactic radiotherapy has also been developed.v-" This technique involves the use of a relocatable head frame that can be placed in different positions during multiple daily treatments." One drawback to this technique is that the relocatable frame does not allow for quite the same degree of accuracy as does a fixed frame. Consequently, approximately 2 mm of additional normal tissue (e.g., cranial Volume 80, Number 10 nerves) is included in the high-dose region. Even so, by delivering several small doses rather than a single large dose, the physician can minimize the risk of cranial nerve palsies when irradiating skull base tumors such as acoustic neuromas and pituitary adenomas, particularly larger tumors (e.g., 3 to 5 cm), [33] [34] [35] [36] Neutron-beam radiotherapy. The Radiation Therapy Oncology Group in North America and the Medical Research Council in Englandjointly conducted a randomized trial to compare fast neutron-beam radiotherapy with conventional photon-beam radiotherapy in patients with incompletely resected or inoperable salivary gland cancers." The trial was stopped after only 32 patients had been enrolled because the results showed that the fastneutron group had experienced significantly better locoregional control. After 10 years of followup, that improvement remains significantly better (65 vs 15%; p = 0.009). However, there was no statistically significant difference in overall survival (15 vs 25%; p>0.05).Most of the failures in the neutron group were attributable to distant metastases, while most failures in the conventional radiotherapy group were the result of locoregional recurrences. Moreover, the neutron group experienced a greater incidence of severe complications, which helps explain why this treatment approach has not gained in popularity. Because locoregional control is more likely to be achieved in patients with salivary gland cancers no larger than 4 em, initial surgical resection is advocated whenever possible." The installation of modem neutron machines and the use of three-dimensional treatment planning at selected institutions should help reduce the relatively high incidence (11%) of severe complications with neutron-beam radiotherapy."
Charged-particle radiotherapy. A small number of facilities around the world deliver radiation with charged particles such as protons and heavy ions ( figure 5 ). Unlike the case with photon and gamma-ray therapy, most of the energy delivered during charged-particle radiotherapy is absorbed at the end of the particles' path through tissue (the Bragg peak phenomenon). The dose unit for these charged particles is called aGy equivalent (GyE). Chargedparticle therapy has not gained much in popularity, in part because the equipment costs tens of millions of dollars to purchase and maintain. Also, there is only a limited number of indications (e.g., unresectable skull base and cervical spine tumors and choroidal melanomas) for which charged-particle therapy is more advantageous than traditional radiotherapeutic techniques. In the case of skull base tumors, the advantage of charged-particle radiotherapy is that it allows for the deposition of highly localized energy within the tumor as it spares the adjacent normal structures.
Since the 1980s, physicians at the Massachusetts General Hospital, Harvard Cyclotron Laboratories, Lawrence 
. Color-wash displays show the dose distributions at three different axial levels on IMRT and 3D-CRT in a patient with a carcinoma involving the right nasal cavity and ethmoid sinus. Note that for a given tumor dose, the radiation dose delivered to the brain and optic pathway by IMRT is lower than that delivered by 3D-CRT.
Berkeley Laboratories, and elsewhere have reported their extensive experience in treating skull base tumors with charged-particle radiotherapy.v" In 1999, Munzenrider and Liebsch updated their experience in using combined photon-proton radiotherapy for chordomas and low-grade chondrosarcomas of the skull base and cervical spine in patients treated between 1975 and 1998. 40 Of the 621 712 patients (52% men) who were analyzed, 60% had chordomas and 40% had chondrosarcomas; 84% had skull base tumors and 16% had cervical spine tumors. Local control was defined as the absence of tumor enlargement on followup imaging in addition to neurologic stability or improvement.
Munzenrider and Liebsch found that among the pa- Urogenilal Disorders: epididymitis, prostatic disorder, abnormal sexual function, amenorrhea, female breast neoplasm, malignant female breast neoplasm, female breast pain, positive cervical smear test, dysmenorrhea, endometrial disorder, intermenstrual bleeding, leukorrhea, menorrhagia, menstrual disorder, ovarian cyst, ovarian disorder, genoal pruritus, uterine hemorrhage, vaginal hemorrhage, atrophic vaginitis, albuminuria, bladder discomfort, increased blood urea nitrogen, dysuria, hematuria, micturition disorder, nephrosis, nocturia, increased nonprotein nitrouen, pyelonephritIS, renal calculus, abnormal renal function, renal pain, strangury, urethral disorder, abnormal urine, urinary incontinence, decreased urine flow, pyuria Inone subject with lupus erythematosus receiving concomitant multiple drug therapy, ahighly elevated ALT level was noted after thefourth week of cevimeline therapy. Intwoother subjects receiving cevimeline intheclinical trials, very high AST levels were noted. The significance ofthese findings is unknown. Additional adverse events (relationship unknown) which occurred inother clinical studies (patient population different from Sjogren's patients) are asfollows: cholinergic syndrome, blood pressure fluctuation, cardiomegaly, postural hypotension, aphasia, convulsions, abnormal abdomen, change in bowel habits, gum hyperplasia, EVOXAC'" Capsules (cevimeline hydrochloride) Inaddition, thefollowing adverse events (~3' 10 incidence) were reported intheSjogren's clinical trials: If medically indicated, atropine, ananti-cholinergic agent may be ofvalue asanantidote foremergency use in patients who have had anoverdose of cevimeline. If medically indicated, epinephrine may also beofvalue inthepresence of severe cardiovascular depression orbronchoconstriction. It is notknown if cevimeline is dialyzable. DOSAGE AND ADMINISTRATION: The recommended dose of cevimeline is30mgtaken three times aday. There is insufficient safety information to support doses greater than 30mgtid.There is also insufficient evidence foradditional efficacy ofcevimeline atdoses greater than 30mgtid. Carcinogenesis, Mulagenesls andImpalrmenl 01Fertility: Lifetime carcinogenicity studies were conducted InCD-l mice and F-344 rats. Astatistically significant increase intheincidence of adenocarcinomas oftheuterus was observed infemale rats thatreceived cevimeline atadosage of100mglkg/day (approximately 8 times themaximum human exposure based oncomparison of AUC data). Noother significant differences intumor incidence were observed in either mice or rats. Cevimeline exhibned noevidence ofmutagenicity orclastogenicity ina battery of assays thatincluded anAmes test, anin vitro chromosomal aberration study in mammalian cells, amouse lymphoma study in L5178Y cells, oramicronucleus assay conducted in vivo in ICR mice. Cevimeline didnotadversely affect thereproductive performance orfertility of male Sprague-Dawley rats when administered for63days prior to mating and throughout theperiod of mating atdosages upto 45mglkg/day (approximately 5 times themaximum recommended dose fora60kghuman following normalization of thedata onthebasis ofbody surface area estimates). Females thatwere treated with cevimeline atdosages upto 45mg/kg/day from 14days prior to mating through day seven of gestation exhibited astatistically significantly smaller number ofimplantations than did control animals. Pregnancy: Pregnancy Category C. Cevimeline was associated with areduction inthemean number ofimplantations when given to pregnant Sprague-Dawley rats from 14days prior to mating through day seven of gestation atadosage of 45mg/kg/day (approximately 5 times themaximum recommended dose fora60kghuman when compared onthebasis ofbody surface area estimates). This effect may have been secondary to maternal toxicity. There are noadequate and well-controlled studies in pregnant women. Cevimeline should be used during pregnancy only if thepotential benefit justifies thepotential risk to thefetus. Nursing Mothers: It isnotknown whether thisdrug is secreted in human milk. Because many drugs are excreted in human milk, and because ofthepotential forserious adverse reactions in nursing infants from EVDXAC'", a decision should bemade whether todiscontinue nursing or discontinue thedrug, taking intoaccount theimportance ofthe drug 10themother. Pediatric Use: Safety and effectiveness inpediatric patients have notbeen established. Gerialrlc Use: Although clinical studies of cevimeline included subjects over theage of 65, thenumbers were notsuf· ficient to determine whether they respond differently from younger subjects. Special care should be exercised when cevimeline treatment isinitiated in anelderly patient, considering thegreater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease orother drug therapy intheelderly. ADVERSE REACTIONS: Cevimeline was administered to 1777 patients during clinical trials worldwide, including Sjogren's patients and patients with other conditions. Inplacebo-controlled Sjogren's studies intheU.S., 320 patients received cevimeline doses ranging from15mgtidto60mgtid,ofwhom 93% were women and 7%were men. Demographic distribution was 90% Caucasian, 5%Hispanic, 3%Black, and 2%of other origin. Inthese studies, 14.6% of patients discontinued treatment wnh cevimeline due to adverse events.
The following adverse events associated with muscannic aaomsm were observed intheclinical trials of cevimeline in Figure 4 . Chart illustrates the volume ofthe parotidgland that was treated to more than 30 Gy with both 3D-CRT and IMRT in seven consecutive patients with nasopharyngeal carcinoma. Following IMRT, these patients did not experience prolonged xerostomia, which is a typical side effect ofconventional 3D-CRT and EBRT. Figure 3 . Axial-view CT images show the distribution of two forms of radiation delivered to a patient with nasopharyngeal cancer. The various colors represent the different doses (cGy) of radiation delivered by IMRT and 3D-CRT. Note that IMRT delivers lower radiation doses to the normal tissues that surround the primary tumor (e.g., the parotid glands) without compromising high doses to the tumor. tients who had skull base tumors, local recurrence-free survival at 10 years was significantly higher among those who had chondrosarcomas than those who had chordomas (94 vs 54%; p<O.OOOl). Likewise, overall IO-year survival was significantly higher among those with chondrosarcomas (88 vs 54%; p<O.OOOl). Among the patients with chondrosarcomas, there was no difference in outcomes between the genders; among those with chordomas, men tended to fare better than women. The probabilities of brainstem or cervical spinal cord injury were 8 and 13% at 5 and 10 years postirradiation, respectively. The probability of temporal lobe injury was 13% at 5 years postirradiation. Optic neuropathy developed in 4.4% of patients. Fifteen of 33 patients (45.5%) who were evaluated prospectively had developed a hearing deficit between 2 and 5 years postirradiation. Almost two-thirds of patients who received 62.7 GyE or more to the inner ear or the auditory nerve experienced a progressive and severe hearing loss. Therefore, Munzenrider and Liebsch concluded that any dose delivered to the inner ear should be limited to no more than 62 GyE.
In two reports of charged-particle radiotherapy conducted at the Lawrence Berke- or neon. Their 5-year local control rate was 63%, and 5year overall survival was 75%.
In the treatment of skull base and cervical spine tumors, the results of charged-particle radiotherapy do compare favorably with those of conventional radiotherapy. However, because charged-particle radiotherapy is expensive and inaccessible, 3D-CRT appears to be a better option for the treatment of skull base tumors. 21, [47] [48] [49] IMRT also shows promise for these tumors.
Intraoperative radiation therapy. During intraoperative radiation therapy (IORT), a single large dose of radiation is delivered in the operating suite after the tumor bed and adjacent normal organs have been defined ( figure 6 ). IORT typically involves the administration of electrons rather than photons. With electrons, the dose of radiation falls off rapidly with depth, and the physician is thus able to spare normal underlying tissues. The typical dose ofIORT is 12 to 20 Gy in a single delivery. Because of the rapid fall-off of the radiation dose with depth, IORT has been investigated as a treatment for head and neck cancer, especially locally advanced or recurrent disease. [50] [51] [52] Freeman et al studied IORT outcomes in 104 patients with head and neck cancer." Forty of these patients underwent surgery and IORT as an initial treatment, while the remainderreceived IORT for recurrent disease. Doses ranged from 15 to 20 Gy. After 2 years, the local control rate was 54%. Patients who had microscopic disease experienced better local control than those with gross disease. The complication rate was 14%. All of the patients who had experienced complications had undergone radiotherapy previously.
In another report, Rate et al published the outcomes of 47 patients with recurrent head and neck cancer who 713 underwent resection and IORTY The 2-year actuarial local control rate was 62%, and the 2-year survival was 55%. Toita et al also reported the outcomes of 25 patients with advanced or recurrent head and neck cancer who were treated with surgery and IORT.52 The 2-yearcontrol rate in the IORT port was 55% for microscopic disease, but 0% for gross disease. The 2-year complication rate was 33%, and there was a higher incidence of complications at doses of 20 Gy and higher. survival was greater (44 vs 25 mo; p = 0.006). The results of this study suggest that organ preservation is possible without a decrement in overall survival.
A recent review" and a meta-analysis of prospective, randomized trials" have suggested that while chemotherapy improves local control, it does so at the cost of increased morbidity. Nevertheless, chemotherapy can lead to an improvement in overall survival when it is administered concurrently with, rather than prior to, radiotherapy.P'" In a phase III randomized study of patients with nasopharyngeal carcinoma, Al-Sarrafet al compared radiotherapy alone with radiation plus concurrentcisplatin chemotherapy for three cycles, followed by 5-fluorouracil and cisplatin for three additional cycles." The radiation doses in both arms were 70 Gy in 35 to 39 fractions, once a day, 5 days per week. At 3 years, the progressionfree survival was significantly better in the combinedmodality group than in the radiotherapy-alone group Figure 6 . An electron treatment cone is docked into position in the operating suite for the delivery of intraoperative radiotherapy to the tumor bed.
1
Chemotherapy Initial studies of patients with recurrent or metastatic head and neck Figure 5 , Graph depicts the energy deposition patterns of Ir1 92 , electrons, neutrons, cancers typically looked at chemo-photons, and charged-particle protons, therapy alone, and the results were disappointing.v-" Next, researchers conducted studies of chemotherapy administered prior to radiotherapy in patients with previously untreated, locally advanced cancers, and two of these randomized trials have been widely quoted by proponents of this approach. 55-57
One of these was a trial conducted by the Department of Veterans Affairs Laryngeal Cancer Study Group.55,56 The VA investigators suggested that natural speech preservation is possible in approximately two-thirds of patients with stage III or IV cancer who undergo three cycles of neoadjuvant 5-fluorouracil and cisplatin chemotherapy followed by EBRT. Patients were randomized to undergo either (1) neoadjuvant chemotherapy and EBRT or (2) total laryngectomy, neck dissection, and postoperative EBRT, After a median followup of33 months, the surgical approach resulted in significantly better locoregional control (p = 0.0005); there was also a trend toward greater disease-free survival (p = 0.11). However, there was no difference in overall survival between the two groups, due in part to the need for surgical salvage of chemoradiation failures.
The other widely quoted study reported the preliminary results of a phase III trial conducted by the European Organization for Research and Treatment of Cancer. 57 In this study, patients with piriform sinus cancer were treated with either (1) two or three cycles of induction 5-fluorouracil and cisplatin chemotherapy followed by radiotherapy or (2) surgery and postoperative radiotherapy. Local control rates were similar in the two arms-83% in the chemotherapy/radiotherapy group and 88% in the surgery/radiotherapy group. Regional control rates were also similar-77 and 81%, respectively. In the chemotherapy/radiotherapy arm, the incidence of distant metastasis was lower (25 vs 36%; p = 0.04), and the median (69 vs 24%; p<O.OOl); the 3-year overall survival rate was better as well (76 vs 46%;p<O.OOl). Based on these findings, the standard of care for stage III or IV nasopharyngeal carcinoma is considered to be radiotherapy with concurrent cisplatin, followed by 5-fluorouracil and cisplatin.
In the past few years, chemotherapy delivered concomitantly with altered fractionation radiotherapy has been investigated in patients with advanced head and neck cancer. 61 -63 Brizel et al at Duke University reported the results of a randomized trial wherein the outcome of twice-daily radiotherapy and concurrent 5-fluorouracil and cisplatin chemotherapy was superior to that of twicedaily radiotherapy alone." One hundred sixteen patients with advanced head and neck cancer were analyzed in this study, which had a median followup of 41 months. At 3 years, locoregional control among patients in the combined-modality group was significantly better than that in the radiotherapy-alone group (70vs44%;p=O.Ol). There was also a trend toward greater relapse-free survival (61 vs 41%) and overall survival (55 vs 34%) in the combined-modality group.
De Serdio et al reported promising results with twicedaily radiotherapy and concurrent carboplatin chemotherapy in 52 stage III and IV head and neck cancer patients." At 52 months, local control and cause-specific survival rates were 72 and 59%, respectively, and the neck control rate was 95%. Because the acute toxicity of chemotherapy with concomitant twice-daily radiotherapy can be severe, this approach should be limited to patients younger than 75 years of age who are able to take care of their own needs.
Preliminary results with radioprotectors such as amifostine'" and glutamine" and chemopreventive agents such as 13-cis retinoic acid 66 ,67 and interferon alfa 66 ,67 have also been encouraging. All of these advances make this an exciting time for physicians who are involved in the multidisciplinary management of head and neck cancers.
